Hakozaki et al collected baseline fecal specimens as an ancillary test in JCOG2007 comparing pembrolizumab and platinum doublet with nivolumab and ipilimumab plus platinum doublet chemotherapy. What gut microbiota signatures closely associated with longer survival in patients receiving chemoimmunotherapy?